🧾 What This Document Is

This is a preliminary proxy statement (PRE 14A) for Puma Biotechnology. It’s like an "information packet and ballot" sent to shareholders before the annual meeting. Its job is to explain what will be voted on and provide the details shareholders need to make informed decisions. The meeting is scheduled for June 11, 2026.

🏢 What The Company Does

👉 In simple terms: Puma Biotechnology is a biopharma company focused on developing and commercializing drugs to treat cancer. Their lead product is NERLYNX, a medicine used to treat certain types of early-stage breast cancer. They are also working on developing other cancer treatments, like a drug called alisertib.

📅 The Big Meeting: What Shareholders Will Vote On

The annual meeting has five main items on the agenda. The Board recommends voting FOR all of them.

Election of Directors (Proposal 1): Shareholders will vote to elect eight people to the board for one-year terms. The nominees are:
- Alan H. Auerbach (Founder & CEO)
- Alessandra Cesano, M.D., Ph.D.
- Allison Dorval
- Michael P. Miller
- Jay M. Moyes (Lead Independent Director)
- Adrian M. Senderowicz, M.D.
- Brian Stuglik, R.Ph.
- Troy E. Wilson, Ph.D., J.D.
Ratify the Accountants (Proposal 2): A routine vote to confirm the selection of KPMG LLP as the company's independent auditor for 2026.
"Say-on-Pay" Vote (Proposal 3): An advisory (non-binding) vote where shareholders express their opinion on the compensation paid to the company's top executives.
The Auerbach Warrant Amendment (Proposal 4): This is a key and specific proposal. Shareholders are being asked to approve extending the expiration date of a stock warrant held by CEO Alan H. Auerbach.
- The Details: The warrant allows the CEO to buy 2,116,250 shares of company stock at a price of $16.00 per share.
- The Ask: Extend its expiration from October 4, 2026, to October 4, 2028.
Other Business: Any other matters that properly come up at the meeting.

⚖️ Big Picture: Governance & Strengths

👍 Strengths & Structure:

Experienced Board: The eight nominees have deep expertise in biotech, finance, commercialization, and clinical development. The average board tenure is 9.2 years.
Independent Oversight: Seven of the eight directors are deemed "independent." The board has separate, active committees for Audit, Compensation, Nominating/Governance, and Research & Development.
Clear Recommendations: The board unanimously supports all proposals, providing clear guidance to shareholders.

⚠️ Risks & Considerations:

CEO-Centric Structure: Alan Auerbach is the Founder, Chairman, CEO, and Secretary. This combined leadership role, while argued to promote efficiency, concentrates significant authority.
Related-Party Proposal (Proposal 4): The vote to extend the CEO's warrant is a direct matter involving executive compensation. Shareholders must evaluate if this extension is in the company's best interest.
Commercial & Clinical Risk: The company's fortunes are heavily tied to the success of NERLYNX and the clinical progress of pipeline drugs like alisertib, which are inherently risky.

💼 Executive Changes

There are no announced changes to the Named Executive Officers (NEOs) in this proxy. The focus is on re-electing the current leadership team.

🔍 The Details: How Voting Works

Record Date: You must have owned shares by the close of business on April 13, 2026, to vote.
Voting Methods: Shareholders can vote by internet, phone, mail, or in person at the meeting.
Quorum Needed: A majority of outstanding shares must be present (in person or by proxy) for the meeting to be valid.
Vote Thresholds:
- Directors are elected by a plurality (the most "For" votes).
- Proposals 2, 3, and 4 require a majority of votes cast.

📞 Contact Information

For questions or assistance with voting, shareholders can contact Investor Relations:

Phone: (424) 248-6500
Email: [email protected]
Address: Puma Biotechnology, Inc., 10880 Wilshire Boulevard, Suite 1700, Los Angeles, California 90024

🧠 The Analogy

Think of this proxy statement as the annual report and agenda for a major homeowners' association (HOA) meeting. The board of directors (the HOA board) is presenting their slate for re-election, proposing the hiring of the same accounting firm (like an auditor), asking for a morale vote on how they've been paid, and putting forward a special rule change that affects one key resident (the CEO). The "Notice and Access" model is like the HOA posting all documents online and sending a postcard with the website link, instead of mailing a huge packet to every homeowner.

🧩 Final Takeaway

This is a standard annual meeting package with a routine set of proposals. The most notable and specific item is Proposal 4, which asks shareholders to approve a two-year extension on a large stock warrant held by the CEO, Alan Auerbach. This vote is a direct signal of shareholder sentiment on a significant component of executive compensation.

PUMA BIOTECHNOLOGY, INC. — PRE 14A Filing